Colorado Clinical and Transational Sciences Institute

科罗拉多临床和转化科学研究所

• 批准号: 9926131
• 负责人: RONALD J. SOKOL
• 金额: $ 792.72万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9926131
• 关键词: Biomedical Research; Child; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Colorado; Communities; Development; Elderly; Ensure; Environment; Evaluation; Funding; Goals; Health; Healthcare; Home environment; Hospitals; Informatics; Infrastructure; Institutes; Interdisciplinary Study; Longevity; Maps; Measurable; Methodology; Methods; Monitor; Multi-Institutional Clinical Trial; Participant; Patient Care; Patients; Performance; Phase; Procedures; Process; Public Health; Rare Diseases; Research; Research Personnel; Research Training; Resources; Safety; Science; Services; System; Time; Training; Training and Education; Translating; Translational Research; Translations; United States National Institutes of Health; Universities; community organizations; cost effective; effective therapy; improved; innovation; named group; next generation; novel; programs; success; translational pipeline; translational scientist

Funded by NIH in 2008 and 2013, the Colorado Clinical and Translational Sciences Institute (CCTSI) at the University of Colorado Denver (CU-D) has taken impressive steps to transform and improve the biomedical; research and training enterprise in the Colorado region and to accelerate and catalyze the translation of discoveries into improved patient care and public health. The CCTSI, a partnership of CU-D, CU Boulder (CU- B), Colorado State University (CSU), six hospitals and 20 community organizations, has established new infrastructure, streamlined processes and expanded existing resources and services for investigators and stakeholders; tripled the number of training and education programs supporting development of a translational workforce; administratively centralized and expanded the breadth of clinical research capacity and expertise; established system-wide informatics capabilities; promoted team science and interdisciplinary research; established an extensive community engagement program and enhanced research across the lifespan; streamlined processes and reduced start-up times for trials; created an academic home for clinical & translational scientists and trainees; and actively engaged in CTSA network activities. Despite these successes, there remain many challenges to accelerating the translational research process locally and nationally. This application maps our path forward to meet these challenges. Through 2018 CTSA funding, we will develop new methods, innovations, expertise, and procedures to: a) achieve a new level of measurable performance in training translational teams, b) improve efficiency and quality of the full spectrum of translational research, c) facilitate multi-site clinical trials, d) engage regional communities and stakeholders as partners, and e) collaborate and disseminate best practices into the national CTSA consortium to accelerate the translation of discoveries into improved health and patient care. We will accomplish these objectives by embracing the following five Overall Strategic Goals: Goal 1: Develop, educate and sustain a diverse translational science workforce to ensure highest research innovation, quality and safety. Goal 2: Create a translational research environment in which team science and collaboration both locally and nationally are facilitated, supported and valued. Goal 3: Engage local and national communities and stakeholders in all phases of the translational research process. Goal 4: Create novel methodologies and resources to support and integrate research in special populations, including children, the elderly, the underserved and those with rare diseases. Goal 5: Further innovate and streamline our processes and enhance our informatics capacity for research start-up, implementation and oversight to promote quality, efficiency, & safety of our research and our active participation in the national CTSA Trial Innovation Network. Special efforts will be made to enhance diversity in our workforce. Our progress will be monitored by our Evaluation Core and we will make mid-course corrections as needed to achieve these goals and ultimately improve the health of our state and the nation.

在2008年和2013年由NIH资助，位于科罗拉多州的科罗拉多临床和转化科学研究所（CCTSI） 科罗拉多丹佛大学（CU-D）已经采取了令人印象深刻的步骤，以改变和改善生物医学; 科罗拉多地区的研究和培训企业，并加速和催化翻译 改善病人护理和公共卫生的新发现。CCTSI是CU-D、CU Boulder（CU- B）、科罗拉多州立大学（CSU）、6家医院和20个社区组织，建立了新的 基础设施，简化程序，扩大现有资源和调查服务， 利益攸关方;将支持翻译发展的培训和教育方案的数量增加两倍 劳动力;行政集中，扩大了临床研究能力和专业知识的广度; 建立全系统的信息学能力;促进团队科学和跨学科研究; 建立了广泛的社区参与计划，并加强了整个生命周期的研究; 简化流程，缩短试验启动时间;为临床和转化研究创建学术之家 科学家和受训人员;并积极参与CTSA网络活动。尽管取得了这些成功，但仍有 许多挑战，以加快本地和国家的转化研究过程。本申请 规划我们的未来之路以应对这些挑战。通过2018年CTSA的资助，我们将开发新的方法， 创新、专业知识和程序，以：a）在培训中实现新的可衡量绩效水平 翻译团队，B）提高全方位翻译研究的效率和质量，C）促进 多中心临床试验，d）让区域社区和利益相关者作为合作伙伴参与，以及e）合作， 向国家CTSA联盟传播最佳实践，以加速将发现转化为 改善健康和病人护理。我们将通过以下五个方面来实现这些目标 战略目标：目标1：发展、教育和维持多样化的转化科学工作队伍，以确保 最高的研究创新，质量和安全。目标2：创造一个转化研究环境， 促进、支持和重视地方和国家的团队科学和协作。目标3：参与 地方和国家社区以及利益相关者参与转化研究过程的各个阶段。目标4： 创建新的方法和资源，以支持和整合特殊人群的研究，包括 儿童、老年人、得不到充分服务的人和患有罕见疾病的人。目标5：进一步创新和精简 我们的进程和提高我们的研究启动，实施和监督的信息能力， 提高我们研究的质量，效率和安全性，并积极参与国家CTSA试验 创新网络。我们将特别努力提高员工队伍的多样性。我们的进步将是 由我们的评估核心进行监测，我们将根据需要进行中期纠正，以实现这些目标 并最终改善我们国家和民族的健康。